High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Polansky, Julia K ^a,d   Bahri, Rajia ^a,b   Divivier, Mylene ^a   Duitman, Erwin H ^a   Vock, Christina ^a   Goyeneche Patino, Diego A ^c   Orinska, Zane ^a   Bulfone Paus, Silvia ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSIDAD COOPERATIVA DE COLOMBIA   (Colombia)

^d Rheumatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; IL15RA PROTEIN, MOUSE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR;

ANIMAL; ANTIGEN PRESENTATION; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; CYTOTOXICITY; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; METASTASIS; MOUSE; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; PEYER PATCH; PHYSIOLOGY; PROMOTER REGION; THYMUS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD11C; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; INTERLEUKIN-15; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASMS; PEYER'S PATCHES; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERLEUKIN-15; THYMUS GLAND;

EID: 84956647693     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19699     Document Type: Article

References (48)

1. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191, 771-780 (2000).
2. Lucas, M., Schachterle, W., Oberle, K., Aichele, P., Diefenbach, A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503-517 (2007).
3. Gordy, L. E. et al. IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 187, 6335-6345 (2011).
4. Zhang, C., Zhang, J., Niu, J., Zhang, J., Tian, Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 42, 128-136 (2008).
5. Giri, J. G. et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. The EMBO journal 13, 2822-2830 (1994).
6. Giri, J. G. et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. The EMBO journal 14, 3654-3663 (1995).
7. Waldmann, T. A., Tagaya, Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17, 19-49 (1999).
8. Castillo, E. F., Schluns, K. S. Regulating the immune system via IL-15 transpresentation. Cytokine 59, 479-490 (2012).
9. Duitman, E. H., Orinska, Z., Bulanova, E., Paus, R., Bulfone-Paus, S. How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Mol Cell Biol 28, 4851-4861 (2008).
10. Mortier, E., Woo, T., Advincula, R., Gozalo, S., Ma, A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205, 1213-1225 (2008).
11. Bergamaschi, C. et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum. Blood 120, e1-8 (2012).
12. Dubois, S., Mariner, J., Waldmann, T. A., Tagaya, Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537-547 (2002).
13. Tamzalit, F. et al. IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci USA 111, 8565-8570 (2014).
14. Stoklasek, T. A., Schluns, K. S., Lefrancois, L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177, 6072-6080 (2006).
15. Asquith, D. L., McInnes, I. B. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 19, 246-251 (2007).
16. Losy, J., Niezgoda, A., Zaremba, J. IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis. Folia Neuropathol 40, 151-153 (2002).
17. Aringer, M. et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 40, 876-881 (2001).
18. Wu, J. IL-15 Agonists: The Cancer Cure Cytokine. J Mol Genet Med 7, 85 (2013).
19. Zhang, X., Sun, S., Hwang, I., Tough, D. F., Sprent, J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
20. Mortier, E. et al. Macrophage-and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31, 811-822 (2009).
21. Ma, L. J., Acero, L. F., Zal, T., Schluns, K. S. Trans-presentation of IL-15 by intestinal epithelial cells drives development of CD8alphaalpha IELs. J Immunol 183, 1044-1054 (2009).
22. Castillo, E. F., Acero, L. F., Stonier, S. W., Zhou, D., Schluns, K. S. Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation. Blood 116, 2494-2503 (2010).
23. Chang, C. L., Lai, Y. G., Hou, M. S., Huang, P. L., Liao, N. S. IL-15Ralpha of radiation-resistant cells is necessary and sufficient for thymic invariant NKT cell survival and functional maturation. J Immunol 187, 1235-1242 (2011).
24. Rosmaraki, E. E. et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 31, 1900-1909 (2001).
25. Chiossone, L. et al. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113, 5488-5496 (2009).
26. Huntington, N. D. et al. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol 178, 4764-4770 (2007).
27. Malaise, M. et al. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J Immunol 192, 1954-1961 (2014).
28. Lee, G. A. et al. Different NK cell developmental events require different levels of IL-15 trans-presentation. J Immunol 187, 1212-1221.
29. Castillo, E. F., Stonier, S. W., Frasca, L., Schluns, K. S. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol 183, 4948-4956 (2009).
30. Stonier, S. W., Ma, L. J., Castillo, E. F., Schluns, K. S. Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood 112, 4546-4554 (2008).
31. Gregoire, C. et al. The trafficking of natural killer cells. Immunol Rev 220, 169-182 (2007).
32. Gillgrass, A., Gill, N., Babian, A., Ashkar, A. A. The Absence or Overexpression of IL-15 Drastically Alters Breast Cancer Metastasis via Effects on NK Cells, CD4 T Cells, and Macrophages. J Immunol 193, 6184-6191 (2014).
33. Takeda, K. et al. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol 90, 777-785 (2011).
34. Bahri, R. et al. IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology 4, e1002721 (2015).
35. Liu, R. B. et al. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res 72, 1964-1974 (2012).
36. Liu, R. B. et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad of Sci USA 110, 8158-8163 (2013).
37. Bezman, N. A. et al. Molecular definition of the identity and activation of natural killer cells. Nature Immunol 13, 1000-1009 (2012).
38. Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33, 74-82 (2015).
39. Zhang, Y. et al. Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology 3, e959321 (2014).
40. Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunol 2, 882-888 (2001).
41. Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nature medicine 17, 604-609 (2011).
42. Chijioke, O., Munz, C. Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol 4, 365 (2013).
43. Sato, N. et al. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Ralpha. Blood 117, 4032-4040 (2011).
44. Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669-676 (1998).
45. Schaefer, M. et al. Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. J Immunoly 180, 6836-6845 (2008).
46. Brocker, T., Riedinger, M., Karjalainen, K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 185, 541-550 (1997).
47. Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223, 77-92 (1999).
48. Galanos, C., Luderitz, O. Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. Eur J Biochem 54, 603-610 (1975).